Two audiences, three years of treatment, and a search vocabulary that belongs to neither.
Allergy immunotherapy search is split between allergists checking prescribing detail and patients searching by symptom and season — with adherence, not acquisition, as the problem worth solving.
Someone who might benefit from immunotherapy is searching for why their symptoms return every spring, whether antihistamines are a permanent answer, or what can be done about a reaction that is worsening year on year. They have almost certainly never encountered the word immunotherapy. Content organised around the treatment name reaches only people who already know it exists, which is a small and largely self-selected group. Symptom-led and season-led material that leads honestly towards the treatment option reaches the population that clinical education alone never will.
The clinical audience is searching for something quite different: allergen extract availability, standardisation and potency units, up-dosing and maintenance schedules, what to do after an interrupted course, and how a preparation is supplied in their market. These are precise, repeated and practical queries, and they are usually answered by a summary of product characteristics that no search engine can read. Publishing that material as accessible, structured content serves the prescriber directly and captures demand that competitors leave sitting in a PDF.
In several markets allergen preparations are supplied individually against a prescription rather than as licensed products with a standard authorisation, and the promotional rules that apply are correspondingly restrictive. This shapes search strategy directly: certain product-level claims cannot be made publicly, and content has to be framed around the allergen, the condition and the prescribing pathway rather than around a product. Establishing that boundary with regulatory colleagues before planning avoids producing material that cannot survive review, which is the usual failure mode here.
Immunotherapy courses run for three years or more and a substantial share of patients abandon them, which costs far more than any acquisition shortfall. Search work that only targets people considering treatment ignores where the value actually leaks. Content answering the questions patients ask mid-course — whether a normal local reaction is a cause for concern, what happens after a missed dose, when improvement should be expected — is searched constantly, competes against almost nothing, and supports the outcome that determines whether a course is completed.
Allergy search demand is sharply seasonal and immunotherapy is typically initiated outside the pollen season, which creates an awkward gap: the searches peak months after the point at which a course should have started. Content published in response to a spring peak arrives far too late to influence that year’s decisions and takes months to gain position in any case. Planning against the clinical calendar rather than the search curve — publishing well before the season so pages are established when demand arrives — is the single most consequential scheduling decision in this category.
Patients are referred into allergy services by general practitioners and paediatricians who may see immunotherapy candidates only occasionally, and who search when they do. Material aimed at that non-specialist referrer — which patients are appropriate, what the referral pathway looks like, what to tell the patient to expect — reaches the point where the decision to refer is actually made. It is a smaller audience than the patient population but a far more decisive one, and it is almost entirely unaddressed across this category.
What comes up when planning search visibility for allergen immunotherapy.
Allergens, conditions and the prescribing pathway rather than products. Clinicians search by allergen and preparation type and need to understand availability, schedules and how to prescribe in their market; patients search by symptom. Neither requires a product catalogue, and organising around one would create promotional problems in markets where these preparations are supplied under named patient arrangements. The allergen-and-pathway structure fits both the search behaviour and the regulatory position.
Disease and treatment education generally yes, product promotion generally no, with the exact line depending on your market. Material explaining allergy, what immunotherapy involves and what to expect during a course can usually be published as health information provided it makes no product claim and names no product. Agreeing that boundary with regulatory colleagues before commissioning anything is what keeps the programme from producing content that is later withdrawn.
Publish for it, but months earlier. Demand peaks in season while immunotherapy is normally initiated out of season, and a new page takes time to establish position regardless. Content published during the peak arrives too late on both counts. The productive pattern is to publish and build authority well ahead, so pages are already ranking when the searches arrive, and to use the peak itself for the adherence and mid-course questions rather than for acquisition.
It is among the highest-value work available here. A general practitioner who recognises an immunotherapy candidate refers not once but repeatedly, and the searches they make are specific, low-competition and directly tied to a referral decision. The audience is small in traffic terms and disproportionate in effect, which is exactly the pattern where conventional volume-based prioritisation gives the wrong answer.
Patients who would benefit and have never heard the word immunotherapy, and courses abandoned in year two for want of an answer to a question asked at midnight. Tell us your markets and we will tell you what we would publish first.